Integra LifeSciences (NASDAQ:IART) Raised to “Hold” at Wells Fargo & Company

Integra LifeSciences (NASDAQ:IART) was upgraded by stock analysts at Wells Fargo & Company to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other research firms have also weighed in on IART. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Citigroup lowered their target price on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Finally, Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $14.40.

Integra LifeSciences Price Performance

IART stock opened at $8.90 on Wednesday. The firm’s fifty day simple moving average is $11.08 and its 200-day simple moving average is $12.73. The company has a market capitalization of $693.67 million, a P/E ratio of -1.32 and a beta of 1.02. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. Integra LifeSciences has a 12 month low of $8.76 and a 12 month high of $23.16.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. The firm had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm’s revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new stake in Integra LifeSciences in the 4th quarter worth $25,000. GAMMA Investing LLC lifted its holdings in Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 913 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. EMC Capital Management acquired a new stake in shares of Integra LifeSciences in the second quarter valued at about $75,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.